- Home
- DOV vs ILMN Comparison
DOV vs ILMN Comparison
Compare DOV & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOV
- ILMN
- Stock Information
- Founded
- DOV 1947
- ILMN 1998
- Country
- DOV United States
- ILMN United States
- Employees
- DOV N/A
- ILMN N/A
- Industry
- DOV Industrial Machinery/Components
- ILMN Medical Specialities
- Sector
- DOV Industrials
- ILMN Health Care
- Exchange
- DOV Nasdaq
- ILMN Nasdaq
- Market Cap
- DOV 27.6B
- ILMN 23.6B
- IPO Year
- DOV N/A
- ILMN 2000
- Fundamental
- Price
- DOV $190.33
- ILMN $135.21
- Analyst Decision
- DOV Buy
- ILMN Buy
- Analyst Count
- DOV 12
- ILMN 17
- Target Price
- DOV $212.83
- ILMN $163.12
- AVG Volume (30 Days)
- DOV 677.8K
- ILMN 2.3M
- Earning Date
- DOV 01-30-2025
- ILMN 02-06-2025
- Dividend Yield
- DOV 1.09%
- ILMN N/A
- EPS Growth
- DOV 53.59
- ILMN N/A
- EPS
- DOV 11.19
- ILMN N/A
- Revenue
- DOV $8,474,513,000.00
- ILMN $4,390,000,000.00
- Revenue This Year
- DOV N/A
- ILMN N/A
- Revenue Next Year
- DOV $5.13
- ILMN $4.05
- P/E Ratio
- DOV $17.29
- ILMN N/A
- Revenue Growth
- DOV 7.02
- ILMN N/A
- 52 Week Low
- DOV $143.97
- ILMN $97.36
- 52 Week High
- DOV $208.26
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- DOV 32.29
- ILMN 40.42
- Support Level
- DOV $186.96
- ILMN $130.31
- Resistance Level
- DOV $203.35
- ILMN $137.69
- Average True Range (ATR)
- DOV 3.19
- ILMN 5.31
- MACD
- DOV -1.70
- ILMN -1.10
- Stochastic Oscillator
- DOV 19.81
- ILMN 22.85
About DOV Dover Corporation
Dover Corp is a diversified manufacturer and solutions provider delivering equipment and components, consumable supplies, aftermarket parts, software digital solutions, and support services. It operates through five segments: engineered systems, clean energy, and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.